The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points.

The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points.

MedLine Citation:	PMID: 10329069 Owner: NLM Status: MEDLINE
Abstract/OtherAbstract:	BACKGROUND: A multicentre study permits rapid recruitment of a large number of patients. However, there is a risk of heterogeneities in end-point evaluations, as complex definitions of criteria are interpreted by several local investigators from different hospitals. Reports discussing end-point evaluation are sparse. The TRIM trial was a multicentre trial of a thrombin inhibitor in patients with unstable angina or non-Q myocardial infarction. In this study, an independent end-point committee evaluated all the reported events of death, acute myocardial infarction and refractory angina pectoris in order to obtain uniform judgements of major end-points. STUDY AIMS: To describe the work of the end-point committee, to analyse its possible effect on the final study results and to discuss the impact on the design of future trials. METHOD: The end-point committee consisted of four members, one from each participating country. After the data were processed by the study monitors, completed case record forms and patient files for patients with reported end-points were mailed to the national member of the end-point committee for judgement. The end-point committee met regularly and made final decisions about the end-points. The work of the end-point committee was documented on a separate case record form. RESULTS: The end-point committee assessed 246 events of death, acute myocardial infarction and refractory angina pectoris in 187 of the 1209 patients (15.5%) in the TRIM trial. Misinterpretation of the index event, an inclusion myocardial infarction, as an early cardiac event was found in 12 patients. After end-point committee judgements, the number of patients with acute myocardial infarction or refractory angina pectoris during 30 days of follow-up was reduced from 177 to 153 (13. 6% reduction). The classification of events was changed in 53 of 187 patients (28.3%) with death, acute myocardial infarction or refractory angina pectoris. The data assessed by the safety committee was significantly different from the final database after end-point committee judgements. CONCLUSION: The end-point committee corrected misinterpretations in such a high proportion of cases that the final results differed significantly from the preliminary results delivered to the safety committee. End-point judgements by an end-point committee should be performed in multicentre clinical trials to improve the quality and reliability of study results.

Authors:	U Näslund; L Grip; J Fischer-Hansen; T Gundersen; S Lehto; L Wallentin
Related Documents :	21242479 - Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling aft... 15093979 - Preinfarction angina does not alter infarct size and in hospital outcome after acute my... 19475779 - Review of nifedipine gits in the treatment of high risk patients with coronary artery d... 1225339 - Arteriographic patterns early in the onset of the coronary syndromes. 21401459 - A new algorithm for the management of stable coronary artery disease incorporating ct c... 21279739 - Merits of non-invasive rat models of left ventricular heart failure. 16183929 - Influence of contrast agent dose and ultrasound exposure on cardiomyocyte injury induce... 9891599 - Medical therapy of chronic heart failure. role of ace inhibitors and beta-blockers. 9487999 - Ovine brain natriuretic peptide in cardiac tissues and plasma: effects of cardiac hyper...
Publication Detail:	Type: Clinical Trial; Journal Article; Randomized Controlled Trial
Journal Detail:	Title: European heart journal Volume: 20 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 1999 May
Date Detail:	Created Date: 1999-07-08 Completed Date: 1999-07-08 Revised Date: 2007-11-15
Medline Journal Info:	Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: ENGLAND
Other Details:	Languages: eng Pagination: 771-7 Citation Subset: IM
Copyright Information:	Copyright 1999 The European Society of Cardiology.
Affiliation:	Heart Centre, University Hospital, Umeå, Sweden.
Export Citation:	APA/MLA Format Download EndNote Download BibTex
MeSH Terms
Descriptor/Qualifier:	Anticoagulants / therapeutic use* Antithrombins / therapeutic use* Coronary Disease / drug therapy, mortality Data Collection Double-Blind Method Glycine / analogs & derivatives, therapeutic use Heparin / therapeutic use* Humans Multicenter Studies as Topic Outcome Assessment (Health Care)* Piperidines / therapeutic use* Randomized Controlled Trials as Topic* Survival Analysis
Chemical
Reg. No./Substance:	0/Anticoagulants; 0/Antithrombins; 0/Piperidines; 0/inogatran; 56-40-6/Glycine; 9005-49-6/Heparin
Comments/Corrections
Comment In:	Eur Heart J. 1999 May;20(10):708-9 [PMID: 10400500 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document: QT dispersion in patients with arrhythmogenic right ventricular dysplasia.
Next Document: Trends in three-year survival following acute myocardial infarction, 1983-1992.